HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools
00
Days
00
Hours
00
Mins
00
Sec
Register Now!
Market News Stocks News ETF News Crypto News

Akari Therapeutics Plc

Contributing Author

Recent Articles by Akari Therapeutics Plc

Nov-25
Akari Therapeutics Announces Release of the Next CEO Corner Segment AKTX GlobeNewswire
Nov-18
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer AKTX GlobeNewswire
Nov-10
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors AKTX GlobeNewswire
Nov-04
Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available AKTX GlobeNewswire
Oct-30
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP AKTX GlobeNewswire
Oct-22
Akari Therapeutics Announces Launch of CEO Corner Platform AKTX GlobeNewswire
Oct-15
Akari Therapeutics Announces $2.5 Million Registered Direct Offering AKTX GlobeNewswire
Oct-09
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 AKTX GlobeNewswire
Oct-03
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting AKTX GlobeNewswire
Sep-24
Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 AKTX GlobeNewswire
Sep-17
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer AKTX GlobeNewswire
Sep-05
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference AKTX GlobeNewswire
Sep-03
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series AKTX GlobeNewswire
Aug-14
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech AKTX GlobeNewswire
Jul-29
Akari Therapeutics Releases Virtual Investor "What This Means" Segment AKTX GlobeNewswire
Jul-23
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers AKTX GlobeNewswire
Jul-22
Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference AKTX GlobeNewswire
Jun-25
Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent AKTX GlobeNewswire
Jun-18
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India AKTX GlobeNewswire
May-29
Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology AKTX GlobeNewswire
May-22
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar AKTX GlobeNewswire
May-15
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update AKTX GlobeNewswire
May-01
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology AKTX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.